Department of Internal Medicine, School of Medicine, Federal University of Ceará, Rua Vicente Linhares, 1198, Fortaleza, Ceará, CEP 60135-270, Brazil,
Int J Clin Pharm. 2014 Aug;36(4):766-70. doi: 10.1007/s11096-014-9955-4. Epub 2014 Jun 17.
Renal abnormalities are often seen in sickle cell disease (SCD).
To investigate the role of hydroxycarbamide as a protective agent in sickle cell nephropathy.
Patients with SCD followed at a Hematology outpatients clinic.
Prospective study with 26 SCD patients. Renal function evaluation was performed and a comparison between patients and control group was done. Patients using hydroxycarbamide were compared to those not taking this drug.
Effect of hydroxycarbamide on renal function.
Patients mean age was 32.1 ± 9.9 years, and 16 (61 %) were males. Glomerular hyperfiltration was found in nine patients with SCD (34.6 %). GFR < 60 mL/min/1.73 m² was observed in three cases (11.5 %). Microalbuminuria (30-300 mg/day) was found in seven cases (27 %) and macroalbuminuria (>300 mg/dia) in one patient (3.8 %). All patients had urinary concentrating deficit, and inability to acidify urine was found in ten cases (38.4 %). The comparison of patients according to the use of hydroxycarbamide showed lower levels of serum creatinine in those using the drug (0.6 ± 0.1 vs. 0.8 ± 0.3 mg/dL, p = 0.03), as well as lower levels of 24 h-proteinuria (226 ± 16 vs. 414 ± 76 mg/dL, p = 0.0001), but not microalbuminuria (79 ± 15 vs. 55 ± 86 mg/dL, p = 0.35).
SCD is associated with important renal abnormalities. Hydroxycarbamide seems to protect kidney function in SCD by decreasing proteinuria but not microalbuminuria.
镰状细胞病（SCD）常伴有肾脏异常。
研究羟基脲作为镰状细胞肾病保护剂的作用。
在血液科门诊就诊的 SCD 患者。
对 26 例 SCD 患者进行前瞻性研究。评估患者肾功能，并与对照组进行比较。比较使用羟基脲和未使用该药物的患者。
羟基脲对肾功能的影响。
患者平均年龄为 32.1 ± 9.9 岁，16 例（61%）为男性。9 例 SCD 患者肾小球滤过率升高（34.6%）。3 例（11.5%）GFR＜60mL/min/1.73m²。7 例（27%）存在微量白蛋白尿（30-300mg/天），1 例（3.8%）存在大量白蛋白尿（＞300mg/dia）。所有患者均存在尿浓缩功能障碍，10 例（38.4%）存在尿液酸化功能障碍。根据使用羟基脲情况对患者进行比较，发现使用该药的患者血清肌酐水平较低（0.6±0.1 比 0.8±0.3mg/dL，p=0.03），24 小时蛋白尿水平较低（226±16 比 414±76mg/dL，p=0.0001），但微量白蛋白尿水平无差异（79±15 比 55±86mg/dL，p=0.35）。
SCD 与严重的肾脏异常有关。羟基脲似乎通过减少蛋白尿而不是微量白蛋白尿来保护 SCD 患者的肾功能。
